Key facts
- It has raised $4.6M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Tech Incubator Program for Startup, Ministry of SMEs and Startups, Kingsley Ventures, Mirae Science and Technology, SM Sino Technology Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Libentech
- ·The full record, as it builds
Funding rounds
No funding rounds for Libentech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Libentech
Operator of a biotechnology platform intended to research and develop biopharmaceutical drugs. The company's platform develops cell lines and virus lines, builds bank systems and various manufactured protein expression platforms, and processes development and document systems, enabling healthcare professionals to have virus development and gene therapy for cancer patients.
- Sector
- Healthcare
- HQ
- Daejeon, South Korea
- Founded
- 2019
- Employees
- 8
- Website
- libentech.kr/
- Ownership
- Privately Held (backing)
Libentech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Libentech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Libentech in its N-PORT filings yet. We sweep new filings monthly.